Monthly Archives: July 2018

JUST EAT plc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / July 31, 2018 / JUST EAT plc (OTC PINK: JSTTY) will be discussing their earnings results in their H1 Earnings Call to be held on July 31, 2018 at 9:30 AM Eastern Time.

To listen to the event live or access a replay of the call – visit https://www.investornetwork.com/company/C-D308A4423C3D6.

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on the what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 507285

Bilibili and Three Additional Stocks Under Scanner in the Internet Space

Stock Research Monitor: BIDU, BITA, and GOOGL

LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on BILI sign up now at www.wallstequities.com/registration. Ahead of today’s trading session, WallStEquities.com follows Baidu Inc. (NASDAQ: BIDU), Bilibili Inc. (NASDAQ: BILI), Bitauto Holdings Ltd (NYSE: BITA), and Alphabet Inc. (NASDAQ: GOOGL). According to a PatSnap report, the Internet Information Providers Industry has a total of 34,367 granted patents and 90,761 patent applications distributed into 62,472 patent families, as of March 12th, 2018. The main technology areas are electric digital data processing, transmission of digital information, and wireless communication networks. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Baidu

On Monday, shares in Beijing, China headquartered Baidu Inc. recorded a trading volume of 2.55 million shares. The stock ended at $251.40, declining 1.45% from the last trading session. The Company’s shares have gained 3.79% in the last month, 0.20% over the previous three months, and 14.27% over the past year. The stock is trading above its 200-day moving average by 1.45%. Furthermore, shares of Baidu, which provides Internet search services in China and internationally, have a Relative Strength Index (RSI) of 44.49.

On July 09th, 2018, research firm KeyBanc Capital Markets upgraded the Company’s stock rating from ‘Sector Weight’ to ‘Overweight’, with a target price of $305 per share.

On July 19th, 2018, Baidu announced that it will report its financial results for Q2 ended June 30th, 2018, after the US market closes on July 31st, 2018. Management will hold an earnings conference call at 9:15 p.m. US ET on July 31st, 2018. A live and archived webcast of this conference call will be available on the Company’s investor relations website. Get the full research report on BIDU for free by clicking below at:

www.wallstequities.com/registration/?symbol=BIDU

Bilibili

Shanghai, China headquartered Bilibili Inc.’s stock finished yesterday’s session 4.45% lower at $11.59. A total volume of 6.68 million shares was traded, which was above their three months average volume of 6.44 million shares. The Company’s shares have gained 6.14% over the previous three months. The stock is trading below its 200-day moving average by 14.53%. Furthermore, shares of Bilibili, which provides online entertainment services for the young generations in China, have an RSI of 35.21. Get access to our top-rated research, including the free report on BILI at:

www.wallstequities.com/registration/?symbol=BILI

Bitauto Holdings

At the close of trading on Monday, shares in Beijing, China headquartered Bitauto Holdings Ltd saw a decline of 2.91%, ending the day at $23.98. The stock recorded a trading volume of 771,459 shares. The Company’s shares have advanced 0.80% in the last month and 13.27% in the previous three months. The stock is trading 1.20% below its 50-day moving average. Moreover, shares of Bitauto Holdings, which through its subsidiaries, provides Internet content and marketing services, and transaction services for the automobile industry in China, have an RSI of 48.74. Click here to subscribe for a free membership which welcomes you with our report on BITA at:

www.wallstequities.com/registration/?symbol=BITA

Alphabet

Mountain View, California headquartered Alphabet Inc.’s shares ended the day 1.82% lower at $1,230.04. A total volume of 2.19 million shares was traded, which was above their three months average volume of 1.85 million shares. The stock has gained 9.16% in the last month, 20.76% over the previous three months, and 28.35% over the past year. The Company’s shares are trading 6.56% above their 50-day moving average and 12.74% above their 200-day moving average. Additionally, shares of Alphabet, which through its subsidiaries, provides online advertising services in the US and internationally, have an RSI of 58.94.

On July 24th, 2018, research firm Stifel reiterated its ‘Buy’ rating on the Company’s stock with an increase of the target price from $1234 a share to $1456 a share. Join our big investor community at Wall St. Equities today and get your free report on GOOGL at:

www.wallstequities.com/registration/?symbol=GOOGL

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 507482

Free Technical Insights on Qurate Retail Group and Three Other Specialty Retail Stocks

Stock Research Monitor: PIR, SBH, and VSI

LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on QRTEA sign up now at www.wallstequities.com/registration. In today’s pre-market research, WallStEquities.com monitors Pier 1 Imports Inc. (NYSE: PIR), Qurate Retail Group Inc. (NASDAQ: QRTEA), Sally Beauty Holdings Inc. (NYSE: SBH), and Vitamin Shoppe Inc. (NYSE: VSI). The Specialty Retail industry consists of automotive, specialty stores, and fuel retailing. The industry is highly fragmented and dependent upon macroeconomic factors such as GDP, disposable income, and consumer spending. Competitive rivalry in this segment is high, with a medium barrier to entry in the market. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Pier 1 Imports

Fort Worth, Texas headquartered Pier 1 Imports Inc.’s stock finished Monday’s session 2.84% higher at $2.17 with a total trading volume of 873,038 shares. The stock is trading below their 50-day moving average by 13.34%. Shares of the Company, which engages in the retail sale of decorative accessories, furniture, candles, housewares, gifts, and seasonal products, have a Relative Strength Index (RSI) of 41.85.

On July 24th, 2018, Pier 1 Imports provided commentary regarding the proposed 10% tariff on additional classes of products imported to the US from China announced by the Office of the US Trade Representative on July 10th, 2018. The Company is evaluating strategies to mitigate the impact of the proposed tariff, including collaborative efforts with its vendor partners, and does not expect financial results in fiscal 2019 to be materially affected. Get the full research report on PIR for free by clicking below at:

www.wallstequities.com/registration/?symbol=PIR

Qurate Retail Group

Shares in Englewood, Colorado-based Qurate Retail Group Inc. ended at $21.16, down 1.03% from the last trading session. The stock recorded a trading volume of 2.35 million shares. The Company’s shares are trading 1.37% below their 50-day moving average. Moreover, shares of the Company, which markets and sells various consumer products primarily through live merchandise-focused televised shopping programs, Websites, and mobile applications, have an RSI of 44.47.

On July 06th, 2018, Qurate Retail announced that its President and CEO, Mike George, and Executive Chairman, Greg Maffei, will host a conference call on August 08th, 2018, at 11:00 a.m. EDT to discuss the Company’s results for Q2 2018. Following the prepared remarks, the Company will host a brief question-and-answer session, during which management will accept questions. QRTEA’s complimentary research coverage is a few simple steps away at:

www.wallstequities.com/registration/?symbol=QRTEA

Sally Beauty Holdings

Denton, Texas headquartered Sally Beauty Holdings Inc.’s stock ended yesterday’s session 0.55% higher at $16.34 with a total trading volume of 1.75 million shares. The stock is trading 3.43% above their 50-day moving average. Shares of the Company, which together with its subsidiaries, operates as a specialty retailer and distributor of professional beauty supplies, have an RSI of 55.57.

On July 16th, 2018, research firm Bank of America/ Merrill downgraded the Company’s stock rating from ‘Neutral’ to ‘Underperform’.

On July 26th, 2018, Sally Beauty said that a press release announcing its Q3 financial results is expected to be made available before the US financial markets open on August 02nd, 2018. The Company will host a conference call and webcast on the same day at 7:30 a.m. CT to discuss the results. This live webcast will be available on the Company’s investor website. Are you already registered with Wall St. Equities? Do so now for free, and get the report on SBH at:

www.wallstequities.com/registration/?symbol=SBH

Vitamin Shoppe

On Monday, shares in Secaucus, New Jersey headquartered Vitamin Shoppe Inc. recorded a trading volume of 348,180 shares. The stock finished 1.91% higher at $8.00. The Company’s shares have advanced 15.11% in the last month and 61.62% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 19.67% and 61.33%, respectively. Furthermore, shares of Vitamin Shoppe, which through its subsidiaries, operates as a omni-channel specialty retailer and contract manufacturer of nutritional products in the US and internationally, have an RSI of 73.00.

On July 27th, 2018, Vitamin Shoppe announced that it will release its Q2 FY18 financial results before the market opens on August 08th, 2018. A conference call will be webcast on the same day beginning at 8:30 a.m. ET. A link to the webcast will be available under the Investor Relations section of the Company’s website. Aspiring Member, please take a moment to register below for your free research report on VSI at:

www.wallstequities.com/registration/?symbol=VSI

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 507483

Free Research Reports on Evoqua Water Technologies and Three More Pollution & Treatment Controls Stocks

Stock Research Monitor: CDTI, CLWT, and LIQT

LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on AQUA sign up now at www.wallstequities.com/registration. WallStEquities.com takes a look at how the following stocks have fared over the past trading sessions: Evoqua Water Technologies Corp. (NYSE: AQUA), CDTI Advanced Materials Inc. (NASDAQ: CDTI), Euro Tech Holdings Co. Ltd (NASDAQ: CLWT), and LiqTech International Inc. (NYSE AMER: LIQT). Companies in the Pollution and Treatment Controls space are engaged in the design, development, and production of filtration systems and pollution control products for consumer and industrial use. These companies, on average, offer dividend yields that are in-line with the wider market. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Evoqua Water Technologies

On Monday, shares in Pittsburgh, Pennsylvania headquartered Evoqua Water Technologies Corp. recorded a trading volume of 237,167 shares. The stock ended the session flat at $20.95. The Company’s shares have gained 1.35% in the last month and 2.55% over the previous three months. The stock is trading 3.65% above its 50-day moving average. Moreover, shares of the Company, which provides a range of water and wastewater treatment systems and technologies, and mobile and emergency water supply solutions and services, have a Relative Strength Index (RSI) of 55.44.

On July 26th, 2018, Evoqua Water Technologies (AQUA) announced that it has completed the acquisition of ProAct Services Corporation from private equity firm, Hammond, Kennedy, Whitney & Company Inc., as previously announced last month. ProAct Services is a leading provider of on-site treatment services of contaminated water in all 50 US states. It will operate as a separate division within AQUA’s Industrial Segment. Get the full research report on AQUA for free by clicking below at:

www.wallstequities.com/registration/?symbol=AQUA

CDTI Advanced Materials

Oxnard, California headquartered CDTI Advanced Materials Inc.’s stock closed the day 1.68% lower at $0.52 with a total trading volume of 136,138 shares. The stock is trading 15.50% below their 50-day moving average. Shares of the Company, which provides technology and solutions to the automotive emissions control markets in the US, Canada, Sweden, France, Japan, Asia, and the UK, have an RSI of 41.03.

On July 25th, 2018, CDTI Advanced Materials announced the closing of its previously announced rights offering. At the closing, the Company issued and sold an aggregate of 4,427,563 shares of its common stock at the subscription price of $0.50 per share, pursuant to the exercise of subscriptions and oversubscriptions in the rights offering from its existing stockholders. The Company received aggregate gross proceeds of approximately $2.2 million from the rights offering before deducting offering expenses. Today’s complimentary research report on CDTI is accessible at:

www.wallstequities.com/registration/?symbol=CDTI

Euro Tech Holdings

Shares in Hong Kong headquartered Euro Tech Holdings Co. Ltd recorded a trading volume of 36,897 shares. The stock ended yesterday’s trading session 5.75% lower at $4.10. The Company’s shares have advanced 2.50% in the past month, 110.92% in the previous three months, and 48.68% over the past year. The stock is trading above its 200-day moving average by 24.51%. Furthermore, shares of Euro Tech, which through its subsidiaries, distributes water treatment equipment, laboratory instruments, analyzers, test kits and related supplies, and power generation equipment in Hong Kong and China, have an RSI of 47.69. Sign up for free on Wall St. Equities and claim the latest report on CLWT at:

www.wallstequities.com/registration/?symbol=CLWT

LiqTech International

Ballerup, Denmark headquartered LiqTech International Inc.’s stock finished Monday’s session 1.18% higher at $0.86 with a total trading volume of 76,028 shares. The Company’s shares have advanced 14.67% in the last month, 114.04% over the previous three months, and 149.49% over the past year. The stock is trading above its 50-day and 200-day moving averages by 17.28% and 73.05%, respectively. Additionally, shares of LiqTech International, which provides technologies for gas and liquid purification by manufacturing ceramic silicon carbide filters, have an RSI of 65.19.

On July 05th, 2018, LiqTech International announced the appointment of Mark E. Vernon as Chairman of its Board of Directors, effective that day, succeeding Aldo Petersen who is retiring from the Board. Mr. Vernon joined the Board in May 2013 and has been serving as the Chairman of the Compensation, Nominating and Governance Committees, as well as a member of the Audit Committee. See the free research coverage on LIQT at:

www.wallstequities.com/registration/?symbol=LIQT

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 507484

Veeva Systems and Three Additional Healthcare Information Services Stocks on Our Research Desk’s Radar

Stock Research Monitor: PINC, RCM, and ATHN

LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on VEEV sign up now at www.wallstequities.com/registration. On Monday, July 30, 2018, the NASDAQ Composite ended the trading session at 7,630.00, down 1.39%; the Dow Jones Industrial Average edged 0.57% lower, to finish at 25,306.83; and the S&P 500 closed at 2,802.60, slightly dropping 0.58%. Losses were broad based as seven out of nine sectors ended the day in negative. This Tuesday, WallStEquities.com has initiated reports coverage on the following Healthcare Information Services equities: Premier Inc. (NASDAQ: PINC), R1 RCM Inc. (NASDAQ: RCM), Veeva Systems Inc. (NYSE: VEEV), and athenahealth Inc. (NASDAQ: ATHN). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Premier

Charlotte, North Carolina headquartered Premier Inc.’s stock finished Monday’s session 0.24% lower at $37.04 with a total trading volume of 342,614 shares. The Company’s shares have advanced 12.28% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 4.45% and 13.97%, respectively. Additionally, shares of Premier, which together with its subsidiaries, operates as a healthcare improvement company in the US, have a Relative Strength Index (RSI) of 57.15. Get the full research report on PINC for free by clicking below at:

www.wallstequities.com/registration/?symbol=PINC

R1 RCM

On Monday, shares in Chicago, Illinois headquartered R1 RCM Inc. recorded a trading volume of 1.65 million shares, which is above its three months average volume of 684.75 thousand shares. The stock ended the session 12.01% lower at $7.91. The Company’s shares have advanced 139.70% over the last twelve months. The stock is trading above its 200-day moving average by 26.78%. Moreover, shares of R1 RCM, which provides revenue cycle management for healthcare providers in the US, have an RSI of 36.62. Free research on RCM can be accessed at:

www.wallstequities.com/registration/?symbol=RCM

Veeva Systems

Pleasanton, California headquartered Veeva Systems Inc.’s shares closed the day 4.86% lower at $75.16. The stock recorded a trading volume of 1.36 million shares, which is above its three months average volume of 986.11 thousand shares. The Company’s shares have gained 18.12% over the last twelve months. The stock is trading above its 200-day moving average by 10.04%. Additionally, shares of Veeva Systems, which provides cloud-based software for the life sciences industry in North America, Europe, Asia/Pacific, and internationally, have an RSI of 35.96. Sign up today for the free research report on VEEV at:

www.wallstequities.com/registration/?symbol=VEEV

athenahealth

Shares in Watertown, Massachusetts headquartered athenahealth Inc. finished 1.42% lower at $147.33. The stock recorded a trading volume of 665,688 shares, which is above its three months average volume of 470.64 thousand shares. The Company’s shares have advanced 20.30% in the previous three months. The stock is trading above its 200-day moving average by 5.24%. Furthermore, shares of athenahealth, which together with its subsidiaries, provides network-based medical record, revenue cycle, patient engagement, care coordination, and population health services for medical groups and health systems, have an RSI of 31.01. Wall St. Equities’ research coverage also includes the downloadable free report on ATHN at:

www.wallstequities.com/registration/?symbol=ATHN

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 507485

Stock Performance Review on Dick’s Sporting Goods and Three Other Services Stocks

Stock Research Monitor: SEAS, BGFV, and HIBB

LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on DKS sign up now at www.wallstequities.com/registration. On Monday, benchmark US indices were in bearish colors as the NASDAQ Composite closed the trading session down 1.39%; the Dow Jones Industrial Average edged 0.57% lower; and the S&P 500 was down 0.58%. US markets made broad based losses with seven out of nine sectors finishing the day in red. Pre-market today, WallStEquities.com reviews these four Services stocks: SeaWorld Entertainment Inc. (NYSE: SEAS), Big 5 Sporting Goods Corp. (NASDAQ: BGFV), Dick’s Sporting Goods Inc. (NYSE: DKS), and Hibbett Sports Inc. (NASDAQ: HIBB). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

SeaWorld Entertainment

Orlando, Florida headquartered SeaWorld Entertainment Inc.’s stock finished Monday’s session 2.13% lower at $21.18. A total volume of 1.94 million shares was traded. The Company’s shares have advanced 40.36% over the previous three months and 46.88% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 2.39% and 34.94%, respectively. Furthermore, shares of SeaWorld Entertainment, which together with its subsidiaries, operates as a theme park and entertainment company in the US, have a Relative Strength Index (RSI) of 47.13.

On July 09th, 2018, research firm Wells Fargo downgraded the Company’s stock rating from ‘Outperform’ to ‘Market Perform’. Get the full research report on SEAS for free by clicking below at:

www.wallstequities.com/registration/?symbol=SEAS

Big 5 Sporting Goods

Shares in El Segundo, California headquartered Big 5 Sporting Goods Corp. ended at $6.50, up 2.36% from the last trading session. The stock recorded a trading volume of 257,855 shares. The stock is trading below its 50-day moving average by 15.93%. Moreover, shares of the Company, which operates as a sporting goods retailer in the western US, have an RSI of 36.67. Gain free access to the research report on BGFV at:

www.wallstequities.com/registration/?symbol=BGFV

Dick’s Sporting Goods

Coraopolis, Pennsylvania headquartered Dick’s Sporting Goods Inc.’s stock ended yesterday’s session 1.52% higher at $33.47 with a total trading volume of 1.49 million shares. The Company’s shares have advanced 1.15% over the previous three months. The stock is trading above its 200-day moving average by 5.21%. Additionally, shares of the Company, which operates as a sporting goods retailer primarily in the eastern US, have an RSI of 39.80. Register for your free report coverage on DKS at:

www.wallstequities.com/registration/?symbol=DKS

Hibbett Sports

On Monday, shares in Birmingham, Alabama headquartered Hibbett Sports Inc. recorded a trading volume of 356,838 shares. The stock finished the day 1.94% higher at $23.65. The Company’s shares have advanced 55.08% over the last twelve months. The stock is trading above its 200-day moving average by 5.01%. Furthermore, shares of Hibbett Sports, which together with its subsidiaries, operates athletic specialty stores, have an RSI of 47.55. Get the free research report on HIBB at:

www.wallstequities.com/registration/?symbol=HIBB

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 507486

Free Post Earnings Research Report: 3M’s Sales Soared 7.4%; EPS Jumped 19.0%

Stock Monitor: IDEX Corp. Post Earnings Reporting

LONDON, UK / ACCESSWIRE / July 31, 2018 / If you want access to our free earnings report on 3M Co. (NYSE: MMM), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MMM. The Company reported its financial results on July 24, 2018, for the second quarter of the fiscal year 2018 (Q2 FY18). The diversified technology Company worldwide surpassed analysts’ estimates for revenues in Q2 FY18. Additionally, the Company raised its guidance for the full fiscal year 2018. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for IDEX Corporation (NYSE: IEX), which also belongs to the Industrial Goods sector as the Company 3M. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=IEX

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, 3M most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=MMM

Earnings Highlights and Summary

For Q2 FY18, 3M’s sales advanced 7.4% to $8.39 billion compared to $7.81 billion in Q2 FY17. The growth in sales included a benefit from organic local-currency of 5.6%; acquisitions, net of divestitures, sales growth of 0.8 %; and a benefit from foreign currency translation of 1.0%. The Company’s revenue numbers exceeded analysts’ estimates of $8.32 billion.

For the reported quarter, 3M incurred total operating expenses of $5.99 billion versus $5.66 billion in the year ago comparable period, increasing 5.9% on a y-o-y basis. The Company posted an operating income of $2.40 billion in Q2 FY18, up by 11.5% from $2.15 billion in Q2 FY17.

During Q2 FY18, 3M posted a net income of $1.86 billion compared to $1.58 billion in Q2 FY17, increasing 17.3% on a y-o-y basis. The Company reported diluted earnings per share (EPS) of $3.07 in the reported quarter compared to $2.58 in the year ago corresponding period, reflecting a growth of 19.0% on a y-o-y basis. The Company’s EPS for Q2 FY18 included a benefit from divestiture gain of $0.48 per share, net of related restructuring actions, whereas its EPS for Q2 FY17 included a benefit from divestiture gain of $0.33 per share, partially offset by portfolio and footprint investments. The Company’s reported adjusted EPS were in-line with analysts’ estimates of $2.59.

Segment Details

3M manages its operations in five business segments, namely: (i) Industrial; (ii) Safety and Graphics; (iii) Health Care; (iv) Electronics and Energy; (v) and Consumer.

For Q2 FY18, the Industrial segment’s sales grew 6.9% to $3.15 billion compared to $2.95 billion in Q2 FY17. The segment’s operating income was $724.0 million in the reported quarter, up by 27.5% from $568.0 million in the prior year’s same period.

The Safety and Graphics segment’s sales increased 15.7% to $1.82 billion in Q2 FY18 compared to $1.57 billion in Q2 FY17. The segment’s operating income declined 43.6% to $480.0 million in Q2 FY18 compared to $851.0 million in Q2 FY17.

During Q2 FY18, the Health Care segment’s sales surged 4.9% to $1.52 billion compared to $1.45 billion in Q2 FY17. The segment’s operating income was $435.0 million in the reported quarter versus $408.0 million in the comparable quarter, increasing 6.6% on a y-o-y basis.

For the reported quarter, the Electronics and Energy segment’s sales increased 3.6% to $1.34 billion compared to $1.29 billion in the corresponding quarter of last year. The segment’s operating income zoomed 166.2% to $865.0 million in Q2 FY18 compared to $325.0 million in Q2 FY17.

The Consumer segment generated sales of $1.22 billion in the reported quarter, up by 4.6% from $1.17 billion in year earlier same quarter. The segment’s operating income jumped 31.8% to $261.0 million in Q2 FY18 compared to $198.0 million in Q2 FY17.

Cash Matters

As of June 30, 2018, 3M’s cash and cash equivalents stood at $2.80 billion compared to $2.65 billion as of June 30, 2017. The Company had a long-term debt of $11.29 billion as of June 30, 2018, versus $12.10 billion as of December 31, 2017. For the six months ended June 30, 2018, the Company generated a cash inflow from operating activities of $2.04 billion compared to $2.63 billion in the six months ended June 30, 2017. For the reported quarter, the Company had a free cash flow of $1.53 billion versus $1.34 billion in the comparable quarter of last year.

Outlook

For the full fiscal year 2018, 3M expects EPS to be in the band of $9.08 to $9.38 compared to its prior range of $8.68 to $9.03; and net income to be in the range of $5.5 billion to $5.7 billion. The Company anticipates adjusted EPS to be in the band of $10.20 to $10.45 for FY18 compared to its previous guidance of $10.20 to $10.55. The Company projects organic local-currency sales growth to be in the range of 3% to 4%, and free cash flow conversion to be between 90% and 100% for FY18.

Stock Performance Snapshot

July 30, 2018 – At Monday’s closing bell, 3M’s stock declined 1.11%, ending the trading session at $205.12.

Volume traded for the day: 2.04 million shares.

Stock performance in the last month – up 4.67%; previous three-month period – up 5.52%; and past twelve-month period – up 2.70%

After yesterday’s close, 3M’s market cap was at $121.31 billion.

Price to Earnings (P/E) ratio was at 23.21.

The stock has a dividend yield of 2.65%.

The stock is part of the Industrial Goods sector, categorized under the Diversified Machinery industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

SOURCE: Active-Investors

ReleaseID: 507455

Blog Exposure – CHMP Adopts Positive Opinion for Alnylam’s Patisiran for HATTR Amyloidosis Treatment

Stock Monitor: Anika Therapeutics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / July 31, 2018 / If you want access to our free research report on Alnylam Pharma, Inc. (NASDAQ: ALNY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALNY as the Company’s latest news hit the wire. On July 27, 2018, the Company announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended a positive opinion recommending marketing authorization of patisiran for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults with stage 1 or stage 2 polyneuropathy. If approved by the European Commission (EC), the medicine will be commercialized under the brand name ONPATTRO™. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Anika Therapeutics, Inc. (NASDAQ: ANIK), which also belongs to the Healthcare sector as the Company Alnylam Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ANIK

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Alnylam Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ALNY

SmPC Recommended by CHMP Includes Data from APOLLO Primary and Secondary Endpoints

The CHMP’s positive opinion is based on the evaluation of the effects of patisiran in patients with hATTR amyloidosis and its safety profile as demonstrated in the APOLLO Phase-3 study. In APOLLO, the safety and efficacy of patisiran were evaluated in a diverse, global population of hATTR amyloidosis patients. The study showed that patisiran improved measures of polyneuropathy, quality of life, activities of daily living, ambulation, nutritional status, and autonomic symptoms relative to placebo in adult patients with hATTR amyloidosis. The SmPC recommended by the CHMP includes data from APOLLO primary and secondary endpoints, as well as exploratory cardiac endpoints. The results of the APOLLO study were published on July 05, 2018, in the New England Journal of Medicine (NEJM).

EC Will Review the CHMP’s Recommendation to Deliver its Final Decision

The European Medicines Agency (EMA) reviewed patisiran under the accelerated assessment procedure that is granted to medicines that the CHMP believes are of major interest for public health and therapeutic innovation. A CHMP positive opinion is one of the final steps before marketing authorization is granted by the EC. The EC will now review the CHMP recommendation to deliver its final decision, applicable to all 28 EU member states, plus Iceland, Liechtenstein, and Norway.

Patisiran is Currently Under Priority Review as a Breakthrough Therapy with the FDA

On February 01, 2018, the US Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) for patisiran for the treatment of hATTR amyloidosis. The FDA also granted Alnylam’s request for Priority Review and has set an action date of August 11, 2018, under the Prescription Drug User Fee Act (PDUFA). Patisiran has been granted a Fast Track Designation, a Breakthrough Therapy Designation, and an expanded Orphan Drug Designation for ATTR amyloidosis from the FDA. Regulatory filings in other markets for patisiran, including Japan, are planned for mid-2018.

About Hereditary ATTR Amyloidosis

Hereditary ATTR (hATTR) amyloidosis is an inherited, progressive disease caused by a genetic mutation that results in the misfolding of transthyretin (TTR) proteins. This results in the formation of amyloid fibrils that could deposit in the nerves, heart, and/or gastrointestinal (GI) tract. hATTR amyloidosis symptoms can vary from person to person, depending on which organs or tissues are affected, and can worsen as the disease progresses. Many people remain undiagnosed or misdiagnosed and treatment options for people with this disease are limited.

About Patisiran

Patisiran is an investigational, intravenously administered ribonucleic acid interference (RNAi) therapeutic targeting transthyretin (TTR) in development for the treatment of hereditary ATTR amyloidosis. It is designed to target and silence specific messenger RNA, potentially blocking the production of TTR protein before it is made. This may help to reduce the deposition and facilitate the clearance of TTR amyloid in peripheral tissues and potentially restore function to these tissues.

About Alnylam Pharmaceuticals, Inc.

Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam is a biopharmaceutical organization developing novel therapeutics based on RNAi. The Company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics in three strategic therapeutic areas (STArs), namely: (i) genetic medicines, (ii) cardio-metabolic diseases, and (iii) hepatic infectious diseases.

Stock Performance Snapshot

July 30, 2018 – At Monday’s closing bell, Alnylam Pharma’s stock declined 7.37%, ending the trading session at $96.81.

Volume traded for the day: 1.31 million shares, which was above the 3-month average volume of 731.68 thousand shares.

Stock performance in the previous three-month period – up 2.41%; and past twelve-month period – up 17.16%

After yesterday’s close, Alnylam Pharma’s market cap was at $9.85 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

SOURCE: Active-Investors

ReleaseID: 507456

Free Post Earnings Research Report: American Campus Communities’ Revenues Jumped 12%

Stock Monitor: Equity LifeStyle Properties Post Earnings Reporting

LONDON, UK / ACCESSWIRE / July 31, 2018 / If you want access to our free earnings report on American Campus Communities, Inc. (NYSE: ACC) (“ACC”), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ACC. The Company reported its second quarter fiscal 2018 operating and financial results on July 23, 2018. The real estate investment trust (REIT), which is based in Austin, Texas, surpassed revenue estimates, and also provided its guidance for FY18. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Equity LifeStyle Properties, Inc. (NYSE: ELS), which also belongs to the Financial sector as the Company American Campus Communities. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ELS

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, American Campus Communities most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ACC

Earnings Highlights and Summary

For the second quarter of the fiscal year 2018, ACC’s revenues totaled $201.1 million versus $179.0 million in Q2 2017, and were ahead of analysts’ estimates by $0.71 million. The Company’s operating income totaled $30.9 million in the reported quarter compared to $12.6 million in the prior year’s same quarter. The increase in the Company’s revenues and operating income was primarily due to increased rental rates for the 2017-2018 academic year, development properties completed in 2017, and property acquisitions completed in 2017.

For Q2 2018, ACC’s net income totaled $46.0 million, or $0.33 per fully diluted share, compared to a net loss of $2.8 million, or $0.02 loss per fully diluted share, in Q2 2017. The increase in the Company’s net income versus the prior year’s comparable quarter was primarily due to a gain of $42.3 million from the disposition of real estate in Q2 2018, and the increases in revenues and operating income.

ACC’s funds from operations (FFO) totaled $65.7 million, or $0.47 per diluted share, in Q2 2018 compared to $68.5 million, or $0.50 per diluted share, in Q2 2017. The Company’s FFO-modified (FFOM) was $72.6 million, or $0.52 per diluted share, in the reported quarter compared to $72.8 million, or $0.53 per diluted share, in the year ago corresponding period. ACC’s FFO numbers lagged Wall Street’s estimates of $0.52 per share.

During Q2 2018, ACC’s net operating income (NOI) for same-store properties was $90.8 million, reflecting an increase of 0.1% from Q2 2017. The Company’s same-store property revenues increased by 1.5% y-o-y due to an increase in average rental rates for the 2017-2018 academic year.

ACC’s NOI for the total portfolio was $104.1 million in Q2 2018 versus $94.7 million in Q2 2017, representing an increase of $9.4 million.

Portfolio Update

Developments – ACC noted that it continues to progress on the construction of its 15 owned development and presale development projects, with expected deliveries in Fall 2018 and 2019. The developments total approximately $1.1 billion and are all core Class A assets located on, or pedestrian to, campus in their respective markets. The projects average less than one-tenth of a mile to campus and remain on track to achieve stabilized development yields in the range of 6.25% – 7.0% for developments, and 5.7% – 6.25% for presale developments.

Third-Party Services – During Q2 2018, ACC closed on financing and commenced construction on a third-party on-campus development project with Delaware State University. The Company expects to earn $2.5 million in fees throughout the construction period and expects to provide management services upon the opening of the community in Fall 2019.

Capital Markets – For Q2 2018, ACC placed $330 million of secured mortgage debt on the newly formed joint venture portfolio with a coupon of 4.07%, and the full amount of principal due at maturity in June 2028. Total gross proceeds from the sales transactions in the reported quarter, including the mortgage debt placed on the joint venture portfolio and the prepayment of existing secured mortgage debt, totaled approximately $750 million. The proceeds were used to repay a $300 million term loan scheduled to mature in 2018; a $150 million term loan scheduled to mature in 2021; and a portion of the outstanding balance on the Company’s revolving credit facility.

Outlook

For FY18, ACC is forecasting FFO per diluted share to be in the range of $2.40 to $2.46, and FFOM per diluted share to be in the band of $2.28 to $2.34.

Stock Performance Snapshot

July 30, 2018 – At Monday’s closing bell, American Campus Communities’ stock marginally advanced 0.07%, ending the trading session at $40.71.

Volume traded for the day: 947.57 thousand shares, which was above the 3-month average volume of 922.12 thousand shares.

Stock performance in the previous three-month period – up 4.09%; and past six-month period – up 5.36%

After yesterday’s close, American Campus Communities’ market cap was at $5.59 billion.

Price to Earnings (P/E) ratio was at 72.18.

The stock has a dividend yield of 4.52%.

The stock is part of the Financial sector, categorized under the REIT – Residential industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

SOURCE: Active-Investors

ReleaseID: 507458

Krabbe Disease Treatment Market Emergence of Pharmacological Chaperone Therapy to Boost the Growth of Industry by 2022

Global Krabbe Disease Treatment Market report track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments and research and developments in the market.

Pune, India – July 31, 2018 /MarketersMedia/

The Global Krabbe Disease Treatment Market can reach a significant valuation, exhibiting a steady CAGR over the forecast period of 2016 to 2022, as per a research report published by Market Research Future (MRFR). The market has been growing continuously on account of increasing incidence of Krabbe disease across the globe. Classification of Krabbe disease under orphan disease has propelled the growth of the market.

Pharmaceutical companies receive incentives to develop medicine for rare disease along with reduced fees in protocol assistance and protection from competition after the medicine is marketed. Increased government funding for drug development and easy approvals, tax credits on clinical research, reduction in the amount of registration fees also aid the growth of the market. These factors also promote research and development activities which further boosts the market growth. Increasing awareness about the disease coupled with the development of tests for screening patients is a crucial market driver.

Browse Premium Sample Copy of 80 Premium Pages Krabbe Disease Treatment Market Report Enabled with Competitive Analysis of Niche Segments, Top Players, Comprehensive Research and Key Regions @ https://www.marketresearchfuture.com/sample_request/1833 .

Regulations aimed at free screening of patients irrespective of health insurance cover and government aid for treatment has been a significant driver of the market. Increasing insurance penetration and better reimbursement policies favor the growth of the market and provide future growth opportunities. Approval of various drugs aimed at the treatment of Krabbe disease by FDA too is a vital growth factor.  Advancements in the therapeutics such as the introduction of gene technology in the treatment of Krabbe disease are expected to drive the market significantly in the coming years.

A significant trend which has been pushing the market growth is the emergence of pharmacological chaperone therapy. Pharmacological chaperone is a promising therapeutic approach which uses drugs to stabilize and guide Chaperone, an ineffective enzyme to help it perform normally. However, the growth of the market might be hindered by the limited patient pool for clinical trials. High costs of treatment for Krabbe diseases such as bone marrow transplantation, cord blood transplantation, and others are major restraints. Lack of effective treatment and high costs of development of new drugs and therapies are other restricting factors.

Segmentation

The global Krabbe disease treatment market has been segmented based on type of treatments and end users. By type of treatments, the market has been segmented into anticonvulsant medication, physical therapy, muscle relaxer drugs, bone marrow transplantation and others. By end users, the market has been segmented into hospitals and clinics, research centers, laboratories and others.

Krabbe Disease Treatment Market Regional Analysis

The key markets of the global Krabbe disease treatment market include North America, Europe, Asia Pacific and the Middle East & Africa. North America leads the market for global Krabbe treatment owing to rise in the screening of the disease and government support for the diagnosis and treatment. Europe follows North America closely and is led by the Scandinavian nations such as Finland and Norway. Asia Pacific is poised to grow at the fastest rate due to large unmet needs and growing awareness about the disease in the developing economies of the region. Asia Pacific market is expected to be led by Japan, China, and India. The Middle East and Africa market are expected to exhibit steady growth and led by Israel. However, the African continent is foreseen to yield weak growth due to poor socio-economic conditions and lack of healthcare penetration in the less developed regions of Africa. South Africa and Egypt are likely to be the key contributors.

Competitive Landscape

The global Krabbe disease treatment market is highly competitive with the presence of various large and small vendors. The notable players of the market include Abbott Laboratories, GlaxoSmithKline, Novartis AG, Sanofi-Aventis SA, UCB Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Pfizer, and Shire. The key players are investing heavily in clinical trials and development of new drugs and therapies to gain a competitive edge over the market.

Industry Updates

A new life-saving saliva test has been developed which will allow the screening of newborns for Krabbe disease and various other conditions. The test will facilitate identification even before any symptoms become apparent and has been developed by a Sydney-based pathology lab, Genepath.

Get Discount @ https://www.marketresearchfuture.com/check-discount/1833 .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Info:
Name: Market Research Future
Email: sales@marketresearchfuture.com
Organization: Market Research Future
Address: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India
Phone: +1 646 845 9312

Source URL: https://marketersmedia.com/krabbe-disease-treatment-market-emergence-of-pharmacological-chaperone-therapy-to-boost-the-growth-of-industry-by-2022/386804

For more information, please visit https://www.marketresearchfuture.com/reports/krabbe-disease-treatment-market-1833

Source: MarketersMedia

Release ID: 386804